NMUCX
Price
$11.42
Change
+$0.10 (+0.88%)
Updated
Jul 31 closing price
Net Assets
252.27M
RWMEX
Price
$67.33
Change
-$0.02 (-0.03%)
Updated
Jul 31 closing price
Net Assets
219.02B
Interact to see
Advertisement

NMUCX vs RWMEX

NMUCX vs RWMEX Comparison Chart in %
View a ticker or compare two or three
VS
NMUCX vs. RWMEX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NMUCX is a Buy and RWMEX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RWMEX has more cash in the bank: 219B vs. NMUCX (252M). RWMEX pays higher dividends than NMUCX: RWMEX (1.16) vs NMUCX (0.00). NMUCX was incepted earlier than RWMEX: NMUCX (17 years) vs RWMEX (24 years). NMUCX (2.00) is less costly to investors than RWMEX (0.61). NMUCX is a more actively managed with annual turnover of: 36.00 vs. RWMEX (29.00). RWMEX has a lower initial minimum investment than NMUCX: RWMEX (250) vs NMUCX (1000). NMUCX annual gain was more profitable for investors over the last year : 10.77 vs. RWMEX (6.62). RWMEX return over 5 years is better than : 26.97 vs. NMUCX (-34.89).
NMUCXRWMEXNMUCX / RWMEX
Total Expense Ratio2.000.61328%
Annual Report Gross Expense Ratio2.000.61328%
Fund Existence17 years24 years-
Gain YTD6.3314.810132%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets252M219B0%
Annual Yield % from dividends0.001.16-
Returns for 1 year10.776.62163%
Returns for 3 years15.2426.6657%
Returns for 5 years-34.8926.97-129%
Returns for 10 years-27.9277.48-36%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UUP28.170.03
+0.11%
Invesco DB US Dollar Bullish
MYCI24.68-0.01
-0.06%
State Street® My2029 Corporate Bond ETF
IMCG95.11-0.08
-0.08%
iShares Morningstar Mid-Cap Growth ETF
DVUT26.45-0.24
-0.88%
WEBs Utilities XLU Defined VolETF
BIB96.61-3.71
-3.70%
ProShares Ultra Nasdaq Biotechnology